Onko-Dent G.L. Slomian Sp. j.
- Address
- Ul. Centralna 17, 44-240 Żory, Poland
Onko-Dent G.L. Slomian Sp. j.
Onko-Dent G.L. Slomian Sp. j. is a specialized clinical research center focused on advancing oncology treatment through innovative clinical trials. The center demonstrates particular expertise in genitourinary malignancies, with a strong emphasis on prostate cancer research and precision medicine approaches targeting specific genetic mutations.
- Metastatic castration-sensitive prostate cancer (mCSPC) research
- Targeted therapies for BRCA-mutated and homologous recombination repair (HRR) deficient tumors
- Novel hormonal agent combinations and precision oncology strategies
The center actively participates in sophisticated clinical trials evaluating next-generation therapeutic agents, including PARP inhibitors and other molecularly targeted treatments. Their research focuses on demonstrating superior outcomes through radiographic progression-free survival assessments in genetically defined patient populations, contributing to the advancement of personalized cancer treatment strategies for patients with advanced prostate cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1AstraZeneca AB1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Onko-Dent G.L. Slomian Sp. j.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase III Randomized, Double-Blind, Placebo-Controlled Study of Saruparib (AZD5305) with New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer | AstraZeneca AB | Phase III | Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abiraterone Acetate | 1 | Unknown | 2024-06-27 | 2024-06-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.